Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia.

BACKGROUND/RATIONALE Autoantibodies to islet antigen-2 (IA-2A) and glutamic acid decarboxylase (GADA) are markers for diagnosis, screening, and measuring outcomes in National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) consortia studies. A harmonization program was established to increase comparability of results within and among these studies. METHODS Large volumes of six working calibrators were prepared from pooled sera with GADA 4.8-493 World Health Organization (WHO) units/ml and IA-2A 2-235 WHO units/ml. Harmonized assay protocols for IA-2A and GADA using (35)S-methionine-labelled in vitro transcribed and translated antigens were developed based on methods in use in three NIDDK laboratories. Antibody thresholds were defined using sera from patients with recent onset type 1 diabetes and healthy controls. To evaluate the impact of the harmonized assay protocol on concordance of IA-2A and GADA results, two laboratories retested stored TEDDY study sera using the harmonized assays. RESULTS The harmonized assays gave comparable but not identical results in the three laboratories. For IA-2A, using a common threshold of 5 DK units/ml, 549 of 550 control and patient samples were concordantly scored as positive or negative, specificity was greater than 99% with sensitivity 64% in all laboratories. For GADA, using thresholds equivalent to the 97th percentile of 974 control samples in each laboratory, 1051 (97.9%) of 1074 samples were concordant. On the retested TEDDY samples, discordance decreased from 4 to 1.8% for IA-2A (n = 604 samples; P = 0.02) and from 15.4 to 2.7% for GADA (n = 515 samples; P < 0.0001). CONCLUSION Harmonization of GADA and IA-2A is feasible using large volume working calibrators and common protocols and is an effective approach to ensure consistency in autoantibody measurements.

[1]  Olli Simell,et al.  The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants , 2011, Pediatric diabetes.

[2]  V. Basevi.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[3]  P. Bingley,et al.  Azide and Tween-20 reduce binding to autoantibody epitopes of islet antigen-2; implications for assay performance and reproducibility. , 2009, Journal of immunological methods.

[4]  C. Polychronakos,et al.  The effect of the MHC locus on autoantibodies in type 1 diabetes , 2009, Journal of Medical Genetics.

[5]  John M Lachin,et al.  Type 1 Diabetes TrialNet–An International Collaborative Clinical Trials Network , 2008, Annals of the New York Academy of Sciences.

[6]  S. Virtanen,et al.  The Environmental Determinants of Diabetes in the Young (TEDDY) Study , 2008, Annals of the New York Academy of Sciences.

[7]  Michael Schlosser,et al.  Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2 , 2008, Diabetologia.

[8]  G. Rossi,et al.  Diagnosis and Classification of Diabetes Mellitus The information that follows is based largely on the reports of the Expert Committee on the Diagnosis and Classification of Diabetes (Diabetes Care 20:1183–1197, 1997, and Diabetes Care 26:3160–3167, 2003). , 2008, Diabetes Care.

[9]  Marian Rewers,et al.  The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes , 2007, Proceedings of the National Academy of Sciences.

[10]  W. Tamborlane,et al.  Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes , 2007, Pediatric diabetes.

[11]  J. Hokanson,et al.  Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. , 2003, Diabetes.

[12]  P. Bingley,et al.  Diabetes Antibody Standardization Program: first assay proficiency evaluation. , 2003, Diabetes.

[13]  Å. Lernmark,et al.  The World Health Organization International Collaborative Study for Islet Cell Antibodies , 2000, Diabetologia.

[14]  P. Bingley,et al.  Optimized autoantibody-based risk assessment in family members. Implications for future intervention trials. , 1999, Diabetes care.

[15]  E. Bonifacio,et al.  Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. , 1999, Diabetes.

[16]  M. Rewers,et al.  Antiislet autoantibodies usually develop sequentially rather than simultaneously. , 1996, The Journal of clinical endocrinology and metabolism.

[17]  E. Bonifacio,et al.  High Level of Concordance Between Assays for Glutamic Acid Decarboxylase Antibodies: The First International Glutamic Acid Decarboxylase Antibody Workshop , 1994, Diabetes.